Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $122.50 Average PT from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given a consensus rating of “Moderate Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $122.50.

A number of brokerages have commented on LNTH. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Lantheus Stock Up 0.8 %

Lantheus stock opened at $90.27 on Monday. Lantheus has a 12 month low of $50.20 and a 12 month high of $126.89. The stock has a market cap of $6.28 billion, a P/E ratio of 14.90 and a beta of 0.51. The company’s fifty day simple moving average is $102.48 and its 200-day simple moving average is $97.13.

Institutional Trading of Lantheus

A number of hedge funds have recently bought and sold shares of LNTH. Moloney Securities Asset Management LLC bought a new position in shares of Lantheus during the 3rd quarter worth about $1,066,000. Hancock Whitney Corp raised its holdings in Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after acquiring an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Lantheus in the 2nd quarter valued at approximately $290,000. Van ECK Associates Corp lifted its position in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus during the 3rd quarter worth approximately $25,955,000. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.